Gramicidin D: natural antibiotic for skin and eye infections (Neosporin ingredient)
A natural antibiotic from soil bacteria that kills gram-positive bacteria by punching holes in their membranes; FDA-approved for topical use in products like Neosporin since 1955, not safe to inject or swallow.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Gramicidin D is a naturally occurring linear antibiotic peptide isolated from the soil bacterium Brevibacillus brevis (formerly Bacillus brevis). It is not a single molecular species but a mixture of three closely related 15-amino acid linear peptides — gramicidin A (~85%), gramicidin B (~5%), and gramicidin C (~10%) — that differ only at position 11 (Trp in A; Phe in B; Tyr in C). Each variant inserts into bacterial lipid bilayers and creates a single-file cation channel that collapses gram-positive bacterial membrane potential. Gramicidin D is classified as a membrane-active antimicrobial peptide (AMP) with FDA-approved topical use; it has no approved systemic indication. It is distinct from the cyclic decapeptide gramicidin S, a separate compound from the same organism with a different mechanism.
The stored sequence VGALAVVVWLWLWLW (15 aa) represents the gramicidin A (valine) variant, the dominant (~85%) component of the mixture. The actual molecule contains D-amino acids at alternating positions — positions 2, 4, 6, 8, 10, 12, and 14 are D-form residues essential for the β6.3-helical channel geometry — and the N-terminus is formylated while the C-terminus carries ethanolamine; neither the D-amino acid stereochemistry nor these terminal modifications are captured in the standard one-letter sequence. Gramicidin B and C differ from A only at position 11 (Phe or Tyr instead of Trp).
History
The gramicidin story begins with soil-bacterium-derived antibiotic discovery. In 1939, René Dubos at Rockefeller University demonstrated that Bacillus brevis produced a bactericidal substance active against gram-positive pathogens — among the first demonstrations that soil microorganisms could be exploited as antibiotic sources (Dubos 1939). Dubos named the crude fraction "tyrothricin," which Rollin Hotchkiss and Dubos subsequently separated into two components: tyrocidin (a cyclic peptide) and gramicidin (the linear fraction). The linear fraction — later designated gramicidin D to distinguish it from the independently named gramicidin S — was notable because it was the first antibiotic peptide whose full amino-acid sequence was determined, an achievement by Sarges and Witkop in 1965.
Structural insights followed over the next three decades. Daniel Urry (1971) proposed the head-to-head β6.3-helical (πLD) model for gramicidin A channel formation — a dimer with alternating L and D residues winding a right-handed helix just wide enough for single-file water and ion passage. This model was confirmed by solid-state NMR and X-ray crystallography in the 1990s and became a cornerstone model system for studying membrane protein channel biophysics.
Clinically, gramicidin D was licensed by the FDA in 1955 as a component of Neosporin® (with neomycin and polymyxin B), one of the earliest multi-antibiotic topical formulations for infected conjunctiva and skin wounds (Alzain 2025). Neosporin and similar formulations remain among the most widely used over-the-counter antibiotics globally. Gramicidin D's clinical trajectory has been limited by its toxicity profile at systemic doses, which renders it unsuitable for anything beyond topical application; research interest now focuses primarily on gramicidin analogs with improved selectivity windows and reduced hemolytic activity.
What it does
Gramicidin D's mechanism is unusually well characterized at the atomic level relative to most antimicrobial peptides.
Channel formation: Individual gramicidin monomers insert into one leaflet of the bacterial phospholipid bilayer in a β6.3-helical conformation. Two monomers from opposite bilayer leaflets associate at their formylated N-termini, forming a head-to-head dimer channel that fully spans the hydrophobic core of the membrane. The interior of the channel is approximately 4 Å in diameter — just wide enough for a single file of water molecules and unhydrated monovalent cations.
Cation conductance: The gramicidin channel is highly selective for monovalent cations (Na⁺, K⁺, Rb⁺, Cs⁺, H⁺) and essentially impermeable to divalent cations and anions. In bacteria that maintain Na⁺ and K⁺ gradients across their membranes for metabolic energy, gramicidin channel insertion collapses the transmembrane ion gradient, depolarizes the membrane potential, and disrupts ATP synthesis. The resulting energy failure and ionic dysregulation is bactericidal.
Selectivity for gram-positive bacteria: Gram-positive organisms (e.g., Staphylococcus aureus, Streptococcus pyogenes, Bacillus subtilis) have a single lipid bilayer accessible to hydrophobic channel-forming peptides. Gram-negative bacteria have an outer membrane with lipopolysaccharide that sterically and electrostatically excludes gramicidin D in most conditions, explaining the compound's predominantly gram-positive activity spectrum (Alzain 2025).
Mammalian toxicity: The same channel-forming mechanism that kills bacteria also permeabilizes red blood cell membranes at sufficiently high local concentrations, causing hemolysis. This hemolytic activity is the primary reason gramicidin D is confined to topical use; at the low concentrations achievable in topical formulations, local antimicrobial effect is achieved without systemic exposure sufficient to cause hemolysis (Yang 2025).
Anti-HIV activity: Gramicidin D has demonstrated activity against HIV in vitro as a component of certain topical microbicide formulations. The mechanism is proposed to involve disruption of the viral lipid envelope, though this application remains investigational.
Evidence
- Human: Gramicidin D as a component of Neosporin® (with neomycin and polymyxin B) has demonstrated efficacy for superficial ocular infections (bacterial conjunctivitis, keratitis) and wound infections, with more than 70 years of post-licensure use since FDA approval in 1955. Approximately 9 registered studies involving gramicidin appear on ClinicalTrials.gov, reflecting investigation of new formulations and combination products rather than de novo efficacy demonstration for the established topical indication (Alzain 2025). Post-licensure surveillance has confirmed the absence of significant systemic absorption at topical doses.
- In vitro: The β6.3 head-to-head helical dimer model, originally proposed by Urry (1971), was validated by solid-state ¹³C NMR and crystal structures of gramicidin A in lipid bilayers and organic solvents. The gramicidin channel has become one of the most thoroughly characterized model systems in membrane biophysics, with the key ion selectivity sequence (Cs⁺ > Rb⁺ > K⁺ > Na⁺ > Li⁺) arising from differential dehydration energies at the channel mouth (Dubos 1939). Multiple in vitro studies confirm that hemolytic activity at supraphysiological concentrations results from the same channel-forming mechanism; minimum inhibitory concentrations against S. aureus in topical conditions and hemolytic doses differ by orders of magnitude, establishing the therapeutic window that makes topical use safe (Yang 2025).
Myths and misconceptions
- "Gramicidin D and gramicidin S are the same compound." They are not. Gramicidin D (the Dubos 1939 linear fraction) and gramicidin S (a cyclic decapeptide) are structurally and mechanistically distinct. Both are produced by B. brevis, but they were discovered independently and have different spectra and mechanisms. Gramicidin D forms cation channels; gramicidin S disrupts membranes via a different cyclic peptide mechanism. They are sometimes conflated in antimicrobial peptide reviews, but their pharmacology is not interchangeable.
- "The stored 15-residue sequence is a single pure peptide." The stored sequence VGALAVVVWLWLWLW represents gramicidin A (the dominant ~85% component). Commercial gramicidin D is always a mixture of A, B, and C variants; all three are biologically active and contribute to the preparation's total antibacterial effect. Any synthetic version based solely on the gramicidin A sequence would not replicate the full pharmacology of the natural mixture.
- "Resistance to gramicidin D is emerging as a clinical concern." Unlike broad-spectrum antibiotics, gramicidin D's channel-forming mechanism is tied to fundamental membrane physics rather than specific enzymatic targets, making resistance development much harder. No clinically significant resistance emergence has been documented over seven decades of widespread topical use, in contrast to resistance rates seen with systemic beta-lactams or fluoroquinolones.
Common questions
Q: Why is gramicidin D only used topically if it's bactericidal? A: Gramicidin D's cation-channel mechanism is non-selective at higher concentrations — the same physical disruption that kills bacteria also lyses mammalian red blood cells (hemolysis). At typical topical concentrations in eye drops or ointments, the drug achieves effective local antimicrobial activity without significant systemic absorption or exposure sufficient to cause hemolysis. If administered systemically at doses needed to treat deeper infections, it would cause intravascular hemolysis. This is a fundamental property of membrane-active AMPs that form channels in eukaryotic membranes above a threshold concentration (Yang 2025).
Q: What is the difference between gramicidin D and tyrothricin? A: Tyrothricin is the crude antibiotic fraction isolated by Dubos from B. brevis culture — it contains both gramicidin (the linear peptide fraction, later called gramicidin D) and tyrocidin (a cyclic decapeptide with broader spectrum and higher hemolytic toxicity). Gramicidin D is the purified linear-peptide sub-fraction of tyrothricin. Most modern pharmaceutical preparations specify gramicidin D specifically (not tyrothricin) to ensure a defined composition (Dubos 1939).
Q: Does gramicidin D work against MRSA? A: Gramicidin D retains activity against methicillin-resistant Staphylococcus aureus (MRSA) in topical conditions, because methicillin resistance (mediated by the mecA gene encoding an altered penicillin-binding protein) does not affect membrane ion-channel vulnerability. The drug's activity is independent of beta-lactam targets. This makes it valuable in topical combinations for superficial MRSA skin and eye infections, though its hemolytic properties preclude systemic use.
Known effects
- Bactericidal against gram-positive pathogens — FDA-approved (topical, since 1955; Neosporin® combination)
- Ocular and wound infection treatment — established clinical use in topical formulations
- Hemolysis at systemic concentrations — well-characterized in vitro and in vivo; limits use to topical routes
- Membrane depolarization in bacteria — mechanistic; confirmed by electrophysiology
Safety signals
Gramicidin D has a well-established safety profile at approved topical doses, with more than 70 years of use in Neosporin® and comparable formulations. Hemolysis is the primary safety concern and is concentration-dependent: the compound is confined to topical application precisely because the systemic concentrations required for bactericidal effect against deep infections would cause intravascular hemolysis. At topical doses in ophthalmic or dermatological use, systemic absorption is not considered significant and hemolysis has not been a clinical concern at those exposure levels. Allergic contact dermatitis has been reported with multi-ingredient Neosporin formulations; attribution to individual components (gramicidin D vs. neomycin vs. polymyxin B) requires clinical evaluation. The compound is cytotoxic to human cells at high local concentrations, consistent with its non-selective membrane-channel mechanism (Alzain 2025; Yang 2025).
Regulatory status
- US: FDA-approved as a component in topical antibiotic formulations (Neosporin®) since 1955. Available over-the-counter for skin and eye infections. Not approved for systemic use.
- WADA: No prohibition listed for gramicidin D in its current topical-antibiotic indication.
Mechanism
Gramicidin D adopts a β6.3-helical (πLD) conformation in lipid bilayers, with alternating L and D residues producing a right-handed helix. The tryptophan residues at the C-terminus (positions 11, 13, 15 in gramicidin A) anchor the molecule at the bilayer–water interface via cation–π and hydrogen-bonding interactions, orienting the helix perpendicular to the membrane plane. Two monomers from opposing leaflets dimerize via formyl-group N-terminal contacts to form a 26-residue transmembrane pore. The single-file channel (internal diameter ~4 Å) conducts monovalent cations with selectivity Cs⁺ > Rb⁺ > K⁺ > Na⁺ > Li⁺ — reflecting differential dehydration enthalpies at the channel entry — while excluding divalent cations and anions. In gram-positive bacteria, insertion of gramicidin channels into the cytoplasmic membrane collapses transmembrane ion gradients, depolarizes membrane potential (as confirmed by DiSC3(5) fluorescence assays used in experimental comparisons), and terminates ATP synthesis. The D-amino acids at alternating positions are not merely structural curiosities: they are required for the geometry that allows head-to-head dimerization across the bilayer, and any L-for-D substitution abolishes channel-forming activity (Alzain 2025; Yang 2025).
Related peptides
- Polymyxin B — co-formulated with gramicidin D in Neosporin®; targets gram-negative outer membranes by a distinct lipopolysaccharide-disruption mechanism, complementing gramicidin D's gram-positive spectrum
- Gramicidin S — a cyclic decapeptide produced by the same organism (B. brevis), discovered independently; disrupts membranes via amphipathic β-sheet mechanism rather than channel formation; historically grouped with gramicidin D by name despite unrelated structure and pharmacology
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Could a pill form of gramicidin A kill the dangerous gut bug C. difficile without getting absorbed into the body and causing harm?
C. difficile causes severe, recurring hospital-acquired diarrhea and is growing harder to treat. If this approach works, it could give doctors a bactericidal option that stays inside the gut, where it is needed, while avoiding the blood toxicity that has always ruled gramicidin out as an internal medicine.
When the mouth turns acidic from sugar, does gramicidin kill bacteria by letting their stored acid energy leak out, rather than by the salt disruption most scientists assumed?
If proton leakage turns out to be the main killing mechanism in acidic conditions, it could explain why gramicidin keeps working where other antibiotics fail, and could open a path to using it in mouthwashes or wound gels targeting the organisms behind tooth decay and infected wounds.
Could gramicidin slip into the power stations of cancer cells more easily than into normal red blood cells, giving it a window where it is lethal to tumors but not yet toxic to the body?
If cancer cell mitochondria are genuinely more vulnerable to gramicidin than red blood cells are, it would mean a dose range exists where the peptide disrupts tumors while leaving healthy cells largely intact. That selectivity window, if confirmed, could make gramicidin a starting point for a new class of mitochondria-targeting cancer therapies.
Does gramicidin attack bacterial membranes first mainly because they carry a stronger negative charge, rather than because the peptide changes shape to fit?
If charge is the gating factor, formulators could tune how selectively gramicidin hits bacteria versus human cells by adjusting the acidity of a cream or gel, or by pairing it with agents that alter bacterial surface charge. That would give a rational, predictable way to make gramicidin-based products safer or more potent for specific uses.
▸full evidence table1 metrics
| metric | value | tool |
|---|---|---|
| ranking score | 0.8040136694908142 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | none_monomer |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-23 |
▸citationbibtex
@peptide{pep04425,
sequence = {VGALAVVVWLWLWLW},
target = {antimicrobial},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}